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Abstract 
Vγ9Vδ2 T cell immunotherapy has been shown to be effective in delaying tumour growth in both 
pre-clinical and clinical studies. It has been pointed out the importance of the ability of cells to 
accumulate within tumours and the association with therapeutic efficacy in clinical studies of 
adoptive T cell transfer. We have previously reported that alendronate liposomes (L-ALD) increase 
the efficacy of this therapy after localised or systemic injection of γδ T cells in mice, inoculated with 
ovarian, melanoma, pancreatic or experimental lung metastasis tumour models, respectively. This 
study aimed to examine the organ biodistribution and tumour uptake of human γδ T cells in 
subcutaneous (SC), intraperitoneal (IP) or experimental metastatic lung tumours, established in 
NOD-SCID gamma (NSG) mice using the melanoma cell line A375Pβ6.luc. pre-injected with 
L-ALD. Overall, small variations in blood profiles and organ biodistribution of γδ T cells among the 
different tumour models were observed. Exceptionally, IP-tumour and experimental metastatic 
lung-tumour bearing mice pre-injected with L-ALD showed a significant decrease in liver 
accumulation, and highest uptake of γδ T cells in lungs and tumour-bearing lungs, respectively. 
Lower γδ T cell count was found in the SC and IP tumours. 
Key words: bisphosphonates, γδ T cells, liposomes, adoptive immunotherapy, nitrogen-containing 
bisphosphonates  
Introduction 
Vγ9Vδ2 T cells have been shown to be effective 
as a cell based cancer immunotherapy [1]. A major 
limiting factor to the therapeutic efficacy of cell-based 
immunotherapy is the ability of the immunologically- 
functional T cells to accumulate in tumours [2-4]. In 
clinical studies of adoptive T cell transfer, it was 
found that only a small percentage of the cells reach 
the tumour tissue [2, 3], and that T cells localisation to 
tumour correlates well with positive clinical outcomes 
[3].  
Nitrogen-containing bisphosphonates (N-BPs) 
further increase the efficacy of this immunotherapy in 
both pre-clinical [5-12] and clinical studies [13-15] as 
they lead to the accumulation of phosphorylated 
metabolites that act as natural phospho-antigens for 
Vγ9Vδ2 T cells [16]. Di Carlo et al. demonstrated that 
infiltration of γδ T cells was significantly higher in 
tumours from mice pre-treated with the N-BP, 
zoledronic acid (ZOL), than when injected with γδ T 
cells alone [7]. Similarly, in a study by Santolaria et al., 
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immunohistochemical analysis showed the presence 
of infiltrating γδ T cells only within tumours of NSG 
mice that received both the N-BP, pamidronate and γδ 
T cells [10]. In addition to the need for Vγ9Vδ2 T cells 
to infiltrate the tumours, combining the treatment 
with N-BPs seems to be crucial to achieving positive 
therapeutic outcome in patients. 
Due to the pharmacokinetic properties of N-BPs 
[17], their encapsulation in liposomes can increase 
levels of N-BPs in solid tumours [18, 19]. Using an 
ovarian tumour model established by intraperitoneal 
(IP) inoculation, liposomal alendronate (L-ALD) has 
been shown to be more effective at slowing tumour 
growth than ALD when administered intravenously 
in combination with Vγ9Vδ2 T cells that were injected 
into the peritoneal cavity of mice [9]. Additionally, we 
have recently reported that only the combinatory 
treatment of L-ALD and γδ T cells led to a significant 
reduction in tumour growth in the experimental 
metastatic lung melanoma model, after 3 successive 
intravenous injections [20, 21].  
Uptake of human γδ T cells in mice has been 
mostly examined qualitatively in tumours and other 
organs such as lymph nodes and spleen by 
immunohistochemical analysis [7, 10, 22, 23]. 
Quantitative assessments on whole body and tumour 
biodistribution of γδ T cells have been studied in 
syngeneic [24] or xenograft [23] tumour models 
injecting murine or human γδ T cells, respectively. 
This work aims to quantitatively compare, and for the 
first time, the biodistribution profiles of human 
γδ T cells in immune-compromised mice, implanted 
with human melanoma A375 Pβ6 tumours at three 
different locations: subcutaneous (SC), intraperitoneal 
(IP) or experimental metastatic lung tumours. 
Tumour-bearing mice were pre-injected with free 
form of ALD or L-ALD, followed by infusion of 
γδ T cells. We investigated whether the different 
immunogenicity and tumour microenvironment due 
to the site of tumour implantation will impact the γδ T 
cell biodistribution and localisation to tumours.  
Methods 
Materials 
1,2-distearoyl-sn-glycero-3-phosphoethanolamin
e-N-diethylenetriaminepentaacetic acid (ammonium 
salt) (DSPE-DTPA) was purchased from Avanti Polar 
Lipids, Inc (USA). 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC) and 1,2-dipalmitoyl 1,2- 
distearoyl-sn-glycero-3-phosphoethanolamine-N-[me
thoxy(polyethylene glycol)-2000] (ammonium salt) 
(DSPE-PEG2000) were obtained from Lipoid 
(Germany). Dextrose, cholesterol, sodium chloride, 
phosphate buffered saline (PBS) tablet, N-(2- 
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) 
(HEPES), methanol (Analytical reagent grade), 
chloroform (analytical reagent grade), human AB 
serum (male), ferric chloride hexahydrate, ammoni-
um thiocyanate and copper (II) sulphate pentahydrate 
were purchased from Sigma-Aldrich (UK). Snake 
Skin® dialysis tubing (MWCO 10000 Da) was 
purchased from Thermo-fisher (USA). Dulbecco’s 
modified Eagle’s medium (DMEM), Roswell Park 
Memorial Institute medium (RPMI), GlutaMAX™ 
and antibiotic-antimycotic solution were purchased 
from Invitrogen (UK). Foetal Bovine Serum was 
purchased from First Link (UK). Ficoll-Paque Plus 
was purchased from GE Healthcare (UK). 
Citrate-dextrose Solution was purchased from SLS 
(UK). IL-2 (100U/ml) (Proleukin®) was obtained from 
Prometheus (USA). T Cell Receptor (TCR) Pan 
gamma/delta-FITC and IgG FITC Isotype controls 
were purchased from Beckman Coulter (UK). 
Tropolone and alendronate sodium trihydrate were 
obtained from Alfa Aesar (UK). D-Luciferin was 
obtained from Perkin Elmer (UK). PD-10 and NAP-5 
desalting column was obtained from GE Healthcare 
Life Sciences (UK). Indium-111 chloride (111InCl3)  was 
obtained from Mallinckrodt (NL). Thin layer 
chromatography (TLC) strips for radio-labelling were 
purchased from Agilent Technologies UK Ltd (UK). 
Isoflurane (IsoFlo®) for anaesthesia was purchased 
from Abbott Laboratories Ltd (UK). All reagents were 
used without further purification. 
Preparation of liposomes 
Lipid stock solutions were prepared in 
chloroform/methanol (4:1 v/v) at concentrations of 
20-40 mg/ml and were stored under nitrogen at -20°C 
to avoid degradation. Alendronic acid liposomes 
(L-ALD) were prepared by the thin film hydration 
(TFH) method as previously described [20, 21, 25]. 
DSPC, cholesterol and DSPE-PEG2000 (55:40:5 molar 
volume) were added to a 25 ml round-bottom flask 
and 2 ml chloroform/ methanol (4:1 v/v) was added. 
A thin lipid film was formed upon removal of the 
solvent under reduced pressure using a rotary 
evaporator (Rotavapor® R-210, Buchi UK). The lipid 
film was flushed with nitrogen to remove any 
remaining traces of organic solvent. The film was then 
hydrated with 1 ml of 100 mM ALD in HEPES 
Buffered Saline (HBS; 20 mM HEPES and 150 mM 
NaCl), adjusted to pH 7.4. The liposome suspension 
was left for 1 h at 60 °C and was vortexed (Vortex 
genie 2, Scientific Industries Inc, USA) every 15 min 
[25]. The resulting suspension was stored at 4°C. 
Liposome’s size and polydispersity (PDI) were 
reduced with serial extrusion using the mini-extruder 
(Avanti Polar Lipids, USA) through polycarbonate 
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membranes (Avanti Polar Lipids, USA) with pore 
sizes 0.8 µm (5x), 0.2 µm (5x), 0.1 µm (10x) and 0.08 µm 
(15x), at 60°C. Free ALD was separated from the 
liposomes by dialysis against HBS using a 10 kD 
dialysis bag. L-ALD were prepared at a final lipid 
concentration of 20 mM. 
Physicochemical characterisation of liposomes 
The hydrodynamic diameter, polydispersity 
index and zeta potential of the liposomes were 
measured using the NanoZS (Malvern Instrument, 
UK). Hydrodynamic size, polydispersity index (PDI) 
and zeta potential were measured in disposable 
square polystyrene cuvettes and disposable capillary 
cells, respectively (Malvern Instrument, UK). The 
sample (20 µl) was diluted to 1.5 ml with 10 mM 
sodium chloride. The measurements were carried out 
at room temperature. Three measurements were 
performed, and the mean and standard deviation 
were calculated for each sample. 
Quantification of ALD 
ALD concentrations, for determination of % EE, 
were determined with a copper sulphate-based UV 
detection method [26]. A calibration curve containing 
5 mM empty liposomes and between 0.1-1 mM of free 
ALD, referred to ‘ALD spiked liposomes’ samples, 
was prepared. L-ALD samples to be quantified (or 
standards) were both processed using the Folch 
method prior to quantification. This method disrupts 
the liposomes; allowing the encapsulated ALD to be 
released into the aqueous phase and separating any 
hydrophobic components (cholesterol, lipids etc.) 
from the hydrophilic drug. In brief, chloroform and 
methanol were added to a sample of liposomes at 
8:4:3 (chloroform: methanol: liposomes) volume ratio. 
The sample was then vortexed (Vortex genie 2, 
Scientific Industries Inc, USA) and centrifuged at 
10000 rpm for 10 minutes (Centrifuge 5810 R, 
Eppendorf). Two layers were formed after 
centrifugation and the upper aqueous layer 
containing the ALD was removed and quantified. 
CuSO4 reagent was prepared by dissolving 10 mM 
CuSO4 in deionised water. A 0.5 ml sample of the 
upper aqueous phase was to 0.5 ml of 10 mM CuSO4 
reagent. After 10 minutes, the UV absorbance at 240 
nm was measured with a UV/Vis Spectrophotometer 
(Perkin Elmer, Model: Lambda 35), using HBS as the 
reagent blank. Concentrations were calculated from 
the equation obtained from the ‘ALD spiked 
liposomes’ calibration curve. Encapsulation Efficiency 
(EE %) was calculated was calculated by comparing 
the ALD concentration of liposomes to the 
concentration before purification. The quantity of 
N-BP in each liposome sample was measured three 
times and expressed as mean ± standard. 
Isolation and expansion of Vγ9Vδ2 T cells 
The γδ T cells were isolated and expanded as 
previously described [20, 21].  Blood samples of 20-30 
ml were obtained from healthy volunteers in an 
ethically approved protocol (“Use of Donor Blood 
Samples for Pre-Clinical Development of Active and 
Passive Immunotherapy for Cancer”; Ref.09/H0804/ 
92). The blood sample was added to 5 ml of 
citrate-dextrose solution to prevent clotting. The 
sample was then layered on top of 15 ml of 
Ficoll-Paque Plus and centrifuged at 1150 g for 25 min, 
with no acceleration or break, using a bench 
centrifuge (Centrifuge 5810 R, Eppendorf). The layer 
of cells between the Ficoll-Paque Plus and the plasma 
was then removed and the resulting PBMCs were 
washed twice with PBS and were then suspended in 
RPMI 1640 (containing 10% human AB serum, 1% 
Glutamax and 1% antibiotic-antimycotic solution) at a 
concentration of 3x106 cells/ml. In order to expand 
the Vγ9Vδ2 T cells, the PBMCs were activated with 1 
µg/ml ZOL and 100 U/ml IL-2. Additional medium 
and 100 U/ml IL-2 were added every 2-3 days for 15 
days. 
Flow cytometry analysis of γδ T cells 
On Day 1 and Day 15, 200 µl samples of the cell 
suspension were taken and 5 µl of either T Cell 
Receptor (TCR) Pan γ/δ-FITC antibody or IgG1 FITC 
Isotypic control antibody was added. The cells were 
incubated with the antibodies for 20 min at 4°C before 
1 ml PBS was added. Cells were centrifuged at 1000 
rpm for 5 min in a bench centrifuge (Centrifuge 5810 
R, Eppendorf). The supernatant was discarded and 
the cell pellet was re-suspended in 500 µL of PBS. All 
flow cytometric data were acquired using a Beckman 
Coulter Cytometer FC 500 MPL and were analysed 
using CXP Analysis software (Beckmann Coulter). 
The lymphocyte cell population was gated and the 
number of cells in this gate that express the γδ TCR 
were calculated as a percentage of the total 
lymphocytes.  
Cancer cell line culture conditions 
The cell line A375Pβ6 was created using the 
human melanoma cell line A375P (CRL-3224™), 
which was infected with pBabe retroviruses encoding 
puromycin resistance and cDNA for human β6 
integrin (A375Pβ6), as previously reported [27]. This 
cell line was a kind gift from Prof John Marshall 
(QMUL). The A375Pβ6 cell line was subsequently 
transduced as described [9] with an SFG retroviral 
vector that encodes for firefly luciferase (luc) and 
dsTomato red fluorescent protein to allow tumour 
growth monitoring. Transduced cells were then flow 
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sorted for red fluorescent to obtain a pure 
A375Pβ6.luc cell line. The cell lines were maintained 
at 37°C, 5% CO2 and 5% relative humidity. DMEM 
media was used, supplemented with 10% FBS, 1% 
GlutaMAX™ and 1% Penicillin/Streptomycin. 
Radiolabelling of liposomes 
Liposomes containing alendronate (L-ALD) 
were prepared and characterised for their size, charge 
and drug loading as previously described [20, 21]. 
Compositions are DSPC, cholesterol, DSPE-PEG2000 
and DSPE-DTPA (54:40:5:1 molar volume). Liposomes 
were then radiolabelled with 111In using protocols as 
described previously [20, 21]. In brief, the required 
volume of 111In, containing 1 MBq per mouse for 
gamma counting studies, was added to 2 M 
ammonium acetate buffer (one-ninth of the reaction 
volume, pH 5.5). This was then added to the liposome 
sample (100 μl of 20 mM liposomes/mouse) to give a 
final ammonium acetate concentration of 0.2 M. The 
mixture was incubated for 30 min at room 
temperature with vortexing every 10 min. The 
reaction was quenched by the addition of 0.1 M EDTA 
solution to the mixture (5 % v/v of the reaction 
mixture) to chelate free [111In]. Unbound [111In]EDTA 
was removed using NAP-5 desalting columns 
equilibrated with PBS with the liposomes collected in 
fractions 1-3 (~150 μl per injection dose). Labelling 
efficiency was assessed as previously reported [20].  
Efficiency and stability of the radiolabelled 
liposomes 
Samples of the radiolabelled L-ALD or 
[111In]EDTA were spotted in glass microfibre 
chromatography paper impregnated with silica gel. 
These strips were then developed using a mobile 
phase of 50 mM EDTA in 0.1 M ammonium acetate. 
Strips were placed on a multi-purpose storage 
phosphor screen (Cyclone ®, Packard, Japan) and 
kept in an autoradiography cassette (Kodak Biomax 
Cassette ®) for 10 min. Quantitative autoradiography 
counting was then carried out using a cyclone 
phosphor detector (Packard ®, Australia). The 
labelling stability was tested by incubation of the 
radio-conjugates in the presence or absence of foetal 
bovine serum (FBS). Samples were diluted in 50% FBS 
or PBS [1:2 (v/v)], and incubated for 24 h at 37°C. The 
percentage of [111In] (immobile spot) still conjugated 
to the liposomes was evaluated by TLC, using the 
same protocol as described above.  
Radiolabelling of γδ T cells 
The γδ T cells were isolated and expanded as 
previously described [20] (See Supplementary 
Information). The percentage of γδ T cells obtained 
from healthy volunteers were variable from batch to 
batch, ranging from 0.8 to 28.3 % of the total 
lymphocytes, assessed by flow cytometry. After 
isolation and expansion in culture, γδ T cell 
population generally increased to above 80 % on Day 
15. The number of cells to be used for radiolabelling 
were calculated based on the percentage of γδ T cells 
harvested. Cell were radiolabelled using 
[111In]tropolone following reported methods with 
modification [28-30]. Tropolone was dissolved in 
isotonic HEPES buffered saline (HBS) at a 
concentration of 1 mg/ml to form a stock solution. A 
volume of 111In stock (as 111InCl3), containing 1 MBq (2 
ul/mouse) or 10-15 MBq (20-30 µl/mouse) per mouse 
for gamma counting or SPECT/CT imaging studies, 
respectively, was added to a volume of the tropolone 
stock solution (3.6 or 36-54 ul/mouse) at a ratio of 5:9 
v:v (111InCl3 stock: tropolone stock) allowing for 
[111In]tropolone complex to form. The [111In]tropolone 
mixture was added to the γδ T cells (5 x 106/mouse in 
50 µl) and incubated for 20 minutes in an incubator at 
37°C, 5% CO2 and 5% relative humidity with gentle 
mixing of the cells every 5 min. Any [111In]tropolone 
not incorporated into the cells was removed by 
centrifuging the cells for 10 min at 500 g and 
discarding the supernatant. The cells were washed 
twice with 10 ml PBS and were then finally 
re-suspended in PBS at a concentration of 5 x 106 cells 
per 150 μl.  
Animal models 
All animal experiments were performed in 
compliance with the UK Home Office (1989) Code of 
Practice for the housing and care of Animals used in 
Scientific Procedures. SCID/Beige mice (used in 
SPECT/CT studies) and Male NOD SCID gamma 
(NSG) mice (~20 g), 4-6 weeks old (used in all other 
studies), were obtained from Charles River (UK). 
Subcutaneous (SC) tumours were established by 
injecting 5 x 106 cells A375Pβ6.luc in 100 μl PBS 
subcutaneously into each of the rear-flanks of the 
mouse. The size of the tumour was measured using 
digital callipers and tumour was then determined 
using the equation: 
Tumour Volume (mm3) = (A2Bπ)/6 
where A and B represent the width and the 
length of the tumours, respectively [31]. Experimental 
metastatic lung tumours were established by slowly 
injecting 5 x 105 cells in 100 μl PBS i.v. into the tail 
vein. Intraperitoneal (IP) tumours were established by 
injecting 5 x 106 cells in 100 μl PBS into the 
intraperitoneal cavity. Both of these deep tumour 
models were monitored by detecting the 
bioluminescence emitted from the A375Pβ6.luc cells 
12 min after subcutaneous injection of D-luciferin at 
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150 mg/kg using an IVIS Lumina series III In Vivo 
Imaging system (Perkin-Elmer, USA). Mice were 
imaged on day 6 post-inoculation and subsequently 
every 3-4 days. Images were quantitatively analysed 
by drawing regions of interest around the tissues 
using Living Image 4.3.1 Service Pack 2 software 
(Perkin-Elmer, USA). For tumour inoculation, 
intravenous injection, blood sampling and imaging, 
mice were anesthetised using isoflurane inhalation 
anaesthesia. 
Whole body SPECT/CT imaging of 
radiolabelled γδ T cells in A375Pβ6 tumour 
bearing mice 
Each mouse was injected with 5 x 106 
radiolabelled γδ T cells ([111In]γδ T cells) or the 
equivalent amount of radioactivity as [111In]tropolone 
via tail vein injection. Mice were imaged with 
nanoSPECT/CT scanner (BioscanInc., USA) 0-30 min, 
4 h and 24 h after i.v. administration using isoflurane 
as inhalation anaesthesia. For each mouse, a 
tomography was initially acquired (45 kVp; 1000 ms) 
to obtain parameters required for the SPECT and CT 
scanner, including the starting line, finish line and 
axis of rotation of the acquisition. SPECT scans were 
obtained using a 4-head scanner with 1.4 mm pinhole 
collimators using the following settings: number of 
projections: 24; time per projection: 60 sec and 
duration of the scan 60 min. CT scans were obtained 
at the end of each SPECT acquisition using 45 kVp. All 
data were reconstructed with MEDISO (medical 
Imaging System) and the combining of the SPECT and 
CT acquisitions were performed using VivoQuant 
(Invicro LLC, USA). 
Gamma counting of radiolabelled γδ T cells 
and L-ALD in A375Pβ6-tumour bearing mice 
For L-ALD biodistribution studies, mice were 
injected with [111In]L-ALD (2 μmol lipid) via tail vein 
injection. For the γδ T cell bio-distribution studies, 
mice were pre-injected with PBS, 0.5 μmol ALD or 
L-ALD 24 hours prior to injection with 5 x 106 [111In]γδ 
T cells per mouse. After 24 h, mice were sacrificed and 
the major organs (brain, lung, liver, spleen, kidney, 
heart, stomach and intestine), muscle, skin, bone 
(femur), carcass and tumours were collected, weighed 
and placed in scintillation vials. Additionally, 5 μl 
blood samples were taken from the tail vein at various 
time points (30, 60, 240 and 1440 min for γδ T cells and 
5, 10, 30, 60, 240 and 1440 min for L-ALD). Urine and 
faeces were collected, by housing the mice in 
metabolic cages for 24 h, to determine the excretion 
profile. Each sample was analysed for [111In] specific 
activity using an automated gamma counter (LKB 
Wallac 1282 Compugamma, PerkinElmer, UK) 
together with dilutions of the injected dose with dead 
time limit below 60%. The gamma rays emitted by the 
radioisotope were detected, quantified and corrected 
for physical radioisotope decay by the gamma 
counter. Radioactivity readings (counts per minute) 
were plotted as percentage of injected dose per organ 
(% ID/organ) or percentage of injected dose per gram 
of tissue (% ID/g). The data were expressed as the 
mean of quadruplicate samples ± SD. In the γδ T cells 
biodistribution studies, with 3 tumour models (SC, IP 
and metastatic lung models) and 3 pre-treatments 
(PBS, ALD and L-ALD), a total of 36 mice were used. 
In the [111In]L-ALD biodistribution studies, with 3 
tumour models and one time point, a total of 12 mice 
were used. 
Statistics 
For all experiments, data were presented as 
mean ± SD; n denotes the number of repeats. For in 
vivo studies, significant differences were examined 
using one-way ANOVA. The t-value, degrees of 
freedom and two-tailed significance (p-value) were 
determined. Kruskal-Wallis test followed by Dunn’s 
test was used for multiple groups comparison. * p < 
0.05, ** p < 0.01 and *** p < 0.001 
Results  
L-ALD has comparable tumour uptake in solid 
and metastatic A375Pβ6.luc tumour models 
L-ALD containing 5% DSPE-PEG2000 was 
formulated using the TFH method. To perform 
biodistribution studies, DTPA-containing liposomes 
(DTPA-L-ALD) were formulated by incorporation of 
1 mol % DSPE-DTPA in the formulation, to allow for 
chelation of [111In]. The physicochemical 
characteristics, percentage encapsulation efficiency of 
ALD (% EE), and radiolabelling efficiency are 
summarised in Table 1. A hydrodynamic size of 152.4 
– 156.6 nm, PDI of 0.051 – 0.058, zeta potential of -11.1 
to -12.5 mV and % EE of 5.9 – 6.2 % were obtained for 
L-ALD and DTPA-L-ALD (p > 0.05). 
[111In]DTPA-L-ALD was successfully formed with a 
radiolabelling efficiency of 82.6 ± 4.2 %. 
Characterisation results are comparable to what have 
been reported in our previous study [20]. 
Three tumour models, subcutaneous (SC), 
intraperitoneal (IP) and experimental lung metastatic 
of A375Pβ6.luc tumours were successfully established 
in NSG mice. Tumour monitoring with representative 
bioluminescence images are shown in Figure 1A. The 
biodistribution of [111In]L-ALD at 24 h after i.v. 
injection was quantified in tumour bearing NSG mice 
by gamma counting. This helped us to understand 
whether there are changes in tissue accumulation of 
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L-ALD, particularly among A375Pβ6.luc tumours 
inoculated at different locations in mice, which could 
have an influence on the consequent γδ T cells 
transfer.  
Prolonged blood circulation times were 
observed with ~55 % ID and ~20 % ID still detected in 
the blood after 4 h and 24 h, respectively (Figure 1B) 
among the three tumour models. Low amounts of 
[111In]L-ALD was detected in the urine (1.0 ± 0.4 %) 
and faeces (0.3 ± 0.2 %) (Figure 1D) of SC tumour 
bearing mice. Low amounts of [111In]L-ALD excreted 
to urine and faeces were also observed in the other 
two tumour models (data not shown). Similar 
biodistribution profiles in general were found in the 
three models (Figure 1C). As expected, high levels of 
radioactivity were detected in liver (18.7 – 32.5 % 
ID/g) and spleen (143.4 – 174.7 % ID/g). 
 
Table 1. Characterisation of liposome formulations 
 Size (nm) 
[b], [e] Poly-dispersity Zeta potential (mV) [a], [e] %EE
[c], [e] Radiolabelling 
efficiency
[d], [e] 
L-ALD 156.6 ± 0.9 0.051 ± 0.02 -12.5 ± 0.6 6.2 ± 0.2 - 
DTPA-
L-ALD 152.4 ± 2.9 0.058 ± 0.013 -11.1 ± 0.8 5.9 ± 0.6 82.6 ± 4.2 
[a] Hydrodynamic diameter measured with dynamic light scattering. [b] Analysed 
with electrophoretic light scattering using 10 mM NaCl. [c] Measured with copper 
sulphate UV spectroscopy method. [d] Measured with quantitative 
autoradiography counting. [e] Data are represented as mean ± SD 
 
 
Figure 1. In vivo biodistribution of radiolabelled [111In]L-ALD in A375Pβ6.luc tumours, after single dose administration via tail vein injection in 
NSG mice. (A) Bioluminescence imaging of three A375Pβ6 tumour models in NSG mice. (B) Blood clearance profile of [111In]L-ALD expressed as % ID. (C) Organ 
biodistribution of [111In]L-ALD expressed as per cent injection dose per gram of organ (%ID/g). (D) Uptake of [111In]L-ALD in SC and IP tumour models at 24 h 
expressed as %ID/g. (E) Excretion profile of [111In]L-ALD expressed as % ID. Subcutaneous (SC), intraperitoneal (IP) and pseudo-metastatic lung tumours were 
established by inoculating NSG mice by i.v. injection of 5 x 105 A375Pβ6 cells, i.p. injection of 5 x 105 A375Pβ6 cells and s.c. injection of 5 x 106 A375Pβ6 cells, 
respectively. A375Pβ6 cells were transduced with firefly luciferase and tumour growth was monitored by bioluminescence imaging (IVIS Lumina series III In Vivo 
Imaging system, Perkin-Elmer). Tumours were established for three weeks prior to use. Mice were i.v. injected with [111In]L-ALD at a dose of 2 μmol lipid/mouse. 
Blood samples (5 µl) were taken at 5, 10 and 30 min and 1, 4 and 24 h. Urine and faeces were collected. After 24 h the mice were sacrificed, and liposome uptake was 
quantified by gamma counting. Data was expressed as mean ± SD (n=6-10 mice per group). ** p < 0.01 
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Figure 2. In vivo whole body 3D SPECT/CT imaging of 
[111In]tropolone and [111In]Vγ9Vδ2 T cells in SC-tumour-bearing 
SCID/Beige mice. γδ T cells were radiolabelled by incubation with 
[111In]tropolone. Any [111In]tropolone not incorporated into the γδ T cells was 
removed by centrifugation. Tumour bearing mice were intravenously injected 
with 5 x 106 [111In]γδ T cells or the equivalent amount of [111In]tropolone. The 
mice were imaged immediately and after 4 and 24 h. The γδ T cells go directly 
to the lung and then redistribute to the liver, spleen and kidneys over time. The 
pattern of biodistribution for [111In]tropolone was markedly different to that of 
the [111In]γδ T cells, suggesting that the cells were stably labelled and have been 
successfully purified from any free [111In]tropolone. 
  
[111In]L-ALD uptake in IP tumours was 4.2 ± 2.6 
% ID/g, significantly higher than SC tumours (1.3 ± 
0.8 % ID/g) (p < 0.01). For the lung metastasis model, 
since the cancer nodules in the lung could not be 
isolated, [111In]L-ALD uptake in the whole lung was 
assessed. The uptake in tumour-bearing lung (1.2 ± 1.1 
% ID/g) was not significantly higher than the lungs of 
SC model mice (0.7 ± 0.5 %ID/g) and IP model mice 
(1.0 ± 0.2 %ID/g) (Figure 1C). In comparison between 
the SC and IP tumours, a significantly higher level of 
[111In]L-ALD was detected in IP tumours although 
large variation in the uptake in the collected tumour 
nodules was observed (Figure 1D). The results of 
organ biodistribution profiles of [111In]L-ALD 
expressed as %ID/organ is shown in Figure S1.  
In vivo whole body SPECT/CT imaging of 
γδ T cells in SC-tumour bearing mice 
 γδ T cells were labelled with [111In]tropolone, 
producing [111In]γδ T cells, to enable biodistribution 
assessments in vivo. Tropolone is a safe and cheap 
ionophore for [111In] shuttling across cell membrane. 
Tropolone chelates radionuclides and form a complex 
that allows the radionuclide to be transported across 
the cell membrane and into the cell lumen. This 
method is well-established to radiolabel platelets and 
lymphocytes using [111In] as the radionuclide for in 
vivo studies [28-30]. Upon incubation with cells, 
[111In]Trop gets translocated into the cellular lumen, 
forming the intermediate [111In]Trop-cell. As the 
interaction between [111In] and tropolone is not 
particularly strong, 111In3+ from the [111In]Trop will 
then exchange with proteins and nucleic acids inside 
the cell. Free tropolone molecules leaves the cell 
lumen and the 111In3+ is then entrapped within the 
lumen, thereby resulting in radiolabelled cells. The 
average radiolabelling efficiency of ~60 % was 
achieved (data not shown). The labelling conditions 
are mild, and the radioactivity used was relatively 
low compared to other studies, in which most of the 
cells were expected to remain viable [32].  
Whole body SPECT/CT imaging of [111In] 
γδ T cells in A375Pβ6 SC-tumour-bearing NSG mice, 
was performed to track the kinetic changes in organ 
biodistribution of [111In]γδ T cells up to 24 h 
post-injection (Figure 2). [111In]γδ T cells were shown 
to accumulate in the lungs within 30 min 
post-injection, and redistribute overtime to the liver, 
spleen, and kidney. SPECT/CT imaging of [111In] 
tropolone in mice was also performed as a control. 
The pattern of biodistribution for [111In]tropolone was 
markedly different to that of the labelled γδ T cells, 
showing prolonged circulation and increased kidney 
excretion overtime. The phenomenon of initial high 
accumulation of T cells in lung after intravenous 
injection and the redistribution to liver, spleen and 
kidney at later time points was in line with the 
imaging results reported by others after radiolabelling 
[22, 23]. This suggests that the cells were successfully 
radiolabelled. The signals detected in kidney may 
correspond to the released [111In] from γδ T cells 
which was also suggested by the other studies [22, 23]. 
Altered liver and spleen uptake of γδ T cells 
was observed in mice pre-treated with L-ALD  
SPECT/CT images of γδ T cells in mice bearing 
SC tumours showed only faint signals in the tumours 
due to high accumulation of γδ T cells in lung, liver 
and spleen. Gamma counting, a quantitative method 
with excellent sensitivity, was consequently 
performed to assess the biodistribution profiles of γδ 
T cells at 24 h post-injection in three A375Pβ6.luc 
tumour models. All mice received pre-treatments of 
PBS, free ALD or L-ALD intravenously 24 h prior to T 
cell injection. It is suggested that the subtle alteration 
in the biodistribution of γδ T cells due to variations in 
tumour sites or ALD pre-treatments, that cannot be 
observed by SPECT/CT imaging, can be captured by 
gamma counting. 
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Figure 3. In vivo biodistribution of radiolabelled γδ T cells in A375Pβ6.luc tumour bearing NSG mice, after single dose administration via tail 
vein injection. NSG mice were inoculated with luciferase-expressing A375Pβ6.luc tumour cells to form (A) subcutaneous (SC) (B) intraperitoneal (IP) or (C) 
experimental metastatic lung tumours. Tumours were allowed to establish for three weeks prior to the biodistribution study. Mice were i.v. injected with [111In]γδ 
T cells at a dose of 5 x 106 γδ T cells/mouse. Mice were pre-treated with 0.5 μmol ALD or L-ALD, 24 h prior to injection of γδ T cells. Blood samples (5 µl) were 
taken at 0.5, 1, 4 and 24 h. After 24 h the mice were sacrificed and the biodistribution of γδ T cells was quantified by gamma counting. Results are expressed as percent 
injection dose per gram of organ (%ID/g organ) or % ID/blood for blood samples. Data are expressed as mean ± SD (n=4 mice per group). Statistical significance was 
indicated in comparison to PBS-injected mice. *p < 0.05, (one-way ANOVA). 
 
 In agreement with the SPECT/CT results, the 
liver, spleen and kidney showed the highest 
accumulation of [111In]γδ T cells. Overall, small 
variations in blood profiles and organ biodistribution 
among the different tumour models were observed 
(Figure 3 and Figure S2). Exceptionally, IP-tumour 
and experimental metastatic lung-tumour bearing 
mice pre-injected with L-ALD showed a significant 
decrease in liver accumulation (Figure 3B and C, light 
grey bars, p < 0.05), while only IP-tumour bearing 
mice had an increase in spleen accumulation (Figure 
3B, light grey bars, p < 0.05) compared to PBS-injected 
mice. Changes in kidney and skin accumulation of 
γδ T cells were observed on a random basis. 
Similar blood profiles of [111In]γδ T cells were 
obtained between different tumour models with or 
without receiving pre-injection of free form of ALD or 
L-ALD. An exception was found in experimental lung 
metastasis model with higher amount of 
[111In]γδ T cells measured in the blood in the mice 
with pre-injection of free form of ALD or L-ALD up to 
4 h post-injection compared to the control ones 
pre-injected with PBS. Low levels of [111In]γδ T cells 
were present in the urine (less than 0.1 % ID) and the 
faeces (< 0.5 % ID) in the SC tumour model which 
could be the result of released [111In] as mentioned 
previously.  
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Figure 4. In vivo tumour uptake of radiolabelled [111In]γδ T cells in 
A375Pβ6.luc tumours, after single dose administration via tail vein 
injection in NSG mice. NSG mice were inoculated with the A375Pβ6.luc cell 
line to form subcutaneous (SC), intraperitoneal (IP) or experimental metastatic 
lung tumours. Mice were i.v. injected with 0.5 μmol ALD or L-ALD 24 h prior to 
i.v. injection of [111In]γδ T cells at a dose of 5 x 106 γδ T cells/mouse. (A) 
Tumour uptake of [111In]γδ T cells expressed as % ID/g of tumour in SC and IP 
tumour-bearing mice. (B) Lung uptake of [111In]γδ T cells expressed as % ID/g 
of lung in SC, IP and experimental metastatic lung tumour-bearing mice. 
Pre-injection of ALD or L-ALD did not significantly alter the tumour uptake of 
γδ T cells. Data are expressed as mean ± SD (n=4 mice per group). Statistical 
analysis was down by Kruskal-Wallis test followed by Dunn’s test to compare 
the differences between individual group (* p < 0.05). 
 
γδ T cells uptake varies among the different 
tumour locations  
We compared uptake of [111In]γδ T cells in 
tumours in the three tumour models to examine if 
tumour location influenced their infiltration by 
γδ T cells. Similar and low uptake of γδ T cells in SC 
and IP tumours of 1.0 – 1.5 % ID/g tumour was 
detected (Figure 4A). In the case of the experimental 
metastatic lung tumour model, the uptake in 
tumour-bearing lung as a whole was determined and 
compared to the lung uptake in other models (Figure 
4B). Interestingly, the uptake of γδ T cells in the lungs 
of IP models was significantly higher than that of 
lungs obtained from SC model mice (p < 0.05). The 
amount of γδ T cells in lung metastasis was not 
significantly different to the lung uptake either in SC 
or IP model. Pre-injection of ALD or L-ALD did not 
change the uptake of γδ T cells in any of the tumours 
or lungs in the three models studied. 
Discussion 
While Vγ9Vδ2 T cells have been shown to be 
effective as a cancer immunotherapy [1], especially 
when used in combination with N-BPs [5-15], little is 
known about the in vivo behaviour of human 
γδ T cells in murine models. This is important to find 
out if a correlation between the number of γδ T cells in 
tumour mass and the success of the therapy can be 
established. While the use of human γδ T cells in 
cancer therapy is well established, yet questions 
remain concerning mechanisms involved in recruiting 
these cells to specific tumours in different tissues. This 
is an important issue since localisation to the tumour 
mass is thought to be required for efficacy. Previous 
studies where human γδ T cells were adoptively 
transferred in different tumour models established in 
mice mostly used qualitative, histological approaches 
to address tumour accumulation [7, 10]. In this work a 
highly quantitative and unbiased approach is used to 
measure human γδ T cell accumulation in tumours 
grown in different locations in mice.  
Previously, lipophilic chelators such as tropo-
lone and oxine have been used to radiolabel a variety 
of blood cells for in vivo studies [28-30]. Many studies 
have proved that such mild labelling method and 
condition does not compromise the cell viability. For 
instance, Jin et al. has assessed the impact of labelling 
with [111In]tropolone on cell viability [32]. They 
labelled 5 million primary isolated bone-marrow- 
derived stem cells with up to 18 MBq [111In]tropolone. 
It was reported that more than 90 % of cells were still 
viable on day 14 when 5 million cells were exposed to 
up to 2.5 MBq [111In]tropolone. In another study, Tai et 
al. dual-labelled one million pancreatic islet cells with 
20 MBq [111In]tropolone and implanted the cells in 
kidney in mice for SPECT imaging [33]. By 
immunohistochemistry examination on the excised 
tissues, it was concluded that the injected 
radiolabelled cells remained viable at 24 h after 
transplantation. Chin et al. labelled isolated swine 
mensenchymal stem cells with [111In]oxine and 
yielded 42 MBq/million cells [34]. The cell viability 
was tested up to 48 h after labelling and remained 95 
% at all times. In the study reported by Brenner et al., 
one million hematopoietic progenitor cells were 
radiolabelled with 30 MBq [111In]oxine and the cell 
viability was impaired by 30 % after 48 h incubation 
but was not affected after 24 h incubation [35]. 
Considering the relative low radioactivity doses used 
in this study (i.e. 1 MBq/5 million cells and 10-15 
MBq/5 million cells for gamma counting and SPECT 
imaging, respectively) and the studied time points (up 
to 24 h), it can be anticipated that most of the cells 
were still viable before injecting to animals. 
From SPECT/CT images, it can be observed that 
majority of the radiolabelled γδ T cells accumulated in 
the lungs within 30 min post injection, before being 
redistributed mainly to the liver and spleen over time 
(Figure 2). In contrast, [111In]tropolone alone showed 
prolonged blood circulation and was measured 
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40.6±2.9 % ID in blood at 4 h post-injection by 
γ-counting and remained 16.3±1.8 at 24 h (data not 
shown. The unique kinetic biodistribution pattern of 
adoptively transferred γδ T cells and low levels of γδ 
T cells seen in the peripheral blood after 
administration, even at early time-points, have been 
reported in clinical [14] and pre-clinical studies [24]. 
Interestingly, a similar pattern of biodistribution of 
other types of human T cells, for example chimeric 
antigen receptor (CAR) T cells, have been reported in 
murine models [22], correlating well with our 
SPECT/CT and gamma counting results. Quantitative 
in vivo tissue biodistribution of γδ T cells has been 
studied in syngeneic 4T1 breast cancer model and in 
xenogeneic MDA-MB-231 breast cancer model 
implanted in the mammary fat pad, using [111In]oxine 
[24] and [89Zr]oxine radiolabelling [23], respectively. 
In the former study, the uptake of the indigenous 
mouse [111In]γδ T cells in the 4T1 tumours was 
quantified as 2.6 %ID/g tumour, 48 h post injection. 
In the latter study, tumour uptake of [89Zr]human 
γδ T cells was measured as 1.2 %ID/g tumour 48 h 
post injection. In our study, IP tumours had a similar 
accumulation of γδ T cells to SC tumours of ~1.5 
%ID/g at 24 h post injection. The differences in 
tumour type (breast tumours vs melanoma tumours), 
species origin of the γδ T-cells or the examination time 
after T cell transfer render direct comparison difficult.  
This work represents a pioneering comparative 
study of the accumulation of γδ T cells among 
tumours in different locations. We hypothesise that 
there is a link between level of γδ T cell localisation to 
tumours and efficacy of the therapy. In many cases, 
tumours have metastasised and reside in different 
locations. By studying uptake of γδ T cell in tumours 
in different locations, we hope to gain further insight 
into what types of tumours may benefit from this 
treatment. Several papers have undertaken 
immunohistochemical staining of human γδ T cells in 
tumour-bearing mice in order to look at the effect of 
pre-injection of N-BPs on tumour accumulation of 
γδ T cells. It has been shown that infiltration of γδ T 
cells was significantly (p < 0.05) higher in adrenal 
gland tumours of mice receiving both γδ T cells and 
free ZOL than when injected with γδ T cells alone [7]. 
A similar result was found in another study, which 
used γδ T cells in combination with the N-BP 
pamidronate (PAM). Immunohistochemical analysis 
of SC prostate tumours showed the presence of 
γδ T cells only when mice had been treated with both 
PAM and γδ T cells [10]. Our results showed no 
significant difference in the tumour levels of γδ T cells 
between mice pre-treated with free or liposomal ALD, 
compared to PBS. This is in contrast with a recent 
study by Man et al. which found using gamma 
counting, a technique used in our study, pre-injection 
of liposomal alendronate 4 day previously enhanced 
tumour uptake of [89Zr]γδ T cells from 1.2 % to 2.1 
%ID/g tumour 48 h post the adoptive cell transfer in a 
xenograft breast cancer model [23]. In addition to 
difference in the tumour model between the two 
studies, in our study, the pre-injection of L-ALD and 
gamma counting were performed at 24 h prior and 24 
h post the adoptive cell transfer, respectively. It is 
possible that it was too early to see the increase of γδ T 
cells in tumours using this dosing schedule.  
One may suggest that since no difference in 
tumour levels of γδ T cells was achieved following 
L-ALD injection, this therapy may not be effective in 
sensitising γδ T cells. This is not the case as in our 
recently published work we have shown that human 
IFN-γ was only detected in the serum of the mice 
pre-treated with L-ALD prior to γδ T cells therapy 
[20]. Additionally, only the combinatory treatment of 
L-ALD and γδ T cells led to a significant reduction in 
tumour growth in the experimental metastatic lung 
melanoma model. It is worth mentioning multiple 
injections of γδ T cells were performed in our [20, 21] 
and others’ therapy studies [7, 10] (>3 times, weekly 
based) where an improvement in therapy was 
noticed. 
The lungs in the SC model were shown to have 
γδ T cell uptake of 7.4 ± 3.0 % ID/g lung while 
tumour-bearing lungs had a significantly higher 
uptake of 22.6 ± 7.1 % ID/g lung (p = 0.03) (Figure 4, 
PBS group). Surprisingly but also interestingly, the IP 
model exhibited the highest γδ T cell uptake (37.1 ± 
20.1 % ID/g lung) among the three models. Our 
findings indicate that physiological changes caused 
by the presence of metastatic lung, SC or IP tumours 
lead to a change in the biodistribution of γδ T cells. 
The pulmonary immune status in patients or 
preclinical animal models with peritoneal cancer was 
rarely discussed. Further studies are required to 
confirm the recruitment of γδ T cell by assessing the 
immune cell populations within the tumours and 
tumour draining lymph nodes by flow cytometry or 
immunohistochemistry. 
L-ALD concentrations in lung tumour tissues 
were calculated by extrapolations from gamma 
counting studies. Assuming that ALD does not 
undergo immature release from the liposomes, it is 
expected to reach concentrations in the range of 
4.2-16.15 nmol ALD/g in lung tissues. These 
concentrations, despite being 10-fold lower than 
needed for in vitro studies, seem to be sufficient to 
result in tumour growth delay in vivo [20, 21]. This 
suggests that L-ALD is not homogenously distributed 
throughout the lung tissues, probably with higher 
concentrations in tumour tissues. In the IP model, 
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variable uptake of L-ALD in tumour nodules was 
observed (Figure 1D) which is expected as tumour 
cells spread throughout the peritoneal cavity. Since 
the tumour uptake is a result of passive targeting 
based on the enhanced permeability and retention 
effect, vascularisation status will be varied between 
small and large tumour nodules within the 
peritoneum thus affecting the uptake efficiency. In 
fact, the first liposome-based nanomedicine, Doxil®, 
was approved to treat advanced ovarian cancer [36] 
which is often well vascularised [37]. The relatively 
high uptake of L-ALD in IP tumour nodules indicates 
the therapeutic potential and this feature can be 
utilised in future studies in combination with γδ T cell 
therapy and/or incorporating with tumour targeting 
ligands [38] in the liposomal formulation to treat 
ovarian cancer or peritoneal metastasis. 
Conclusion 
In vivo biodistribution studies of [111In]γδ T cells 
in mice agreed with other reports describing T-cell 
organ biodistribution with highest accumulation in 
the liver and spleen. Despite the comparable L-ALD 
uptake in all tumour types, γδ T cells showed highest 
uptake in the melanoma tumour-bearing lung model 
and lungs of mice implanted in the IP cavity. Lower γδ 
T cell count was found in the SC and IP tumours. 
Dosimetry studies focusing on correlating γδ T cells 
levels in in vivo tumours and therapeutic responses 
may help us understand better the impressively fast- 
growing field of T-cell based immunotherapy. 
Conclusions from the current study can only apply to 
the melanoma tumour model in NSG mice so further 
tests need to be carried out on other types of mice 
tumours. 
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